CURE

The Week

XLV.US closed the week at $170.81, up 2.79%, while the S&P 500 gained 1.15%, leaving XLV.US about 1.64 percentage points ahead of the benchmark. Monday (Oct 5) opened at $166 and settled at $167.37 after a choppy session. Tuesday (Oct 6) faded early strength to close at $167.09. Wednesday (Oct 7) pushed up to $170.38 before finishing at $168.81. Thursday (Oct 8) briefly pulled back to $165.19 and ended at $168.16. Friday (Oct 9) rallied into the close, touching a weekly high of $171.035 and finishing at $170.81. Weekly amplitude was 3.52%, and average daily volume of roughly 8.34m shares ran 11.45% above the median, showing moderately firmer participation.

Sector News

The healthcare sector carried a busy news week, centred on drug-development headlines and regulatory updates. Pfizer’s TUKYSA regimen received FDA approval as first-line maintenance for HER2-positive metastatic breast cancer. AbbVie landed a breakthrough-therapy designation for ABBV-400 in metastatic colorectal cancer and two more FDA breakthrough tags for Temab-A in cancer. Gilead drew attention after an earnings beat, with UBS maintaining a buy rating, while Amgen stayed in focus on MariTide coverage and Cantor Fitzgerald assigned a hold. Lilly released Phase 3b TOGETHER-PsO data showing broader biomarker shifts for Taltz plus Zepbound. On the insurance side, CMS published 2027 ratings and health-plan stocks traded mixed, while the Texas Attorney General opened a probe into UnitedHealth over alleged bribes, care delays and coverage denials. R&D and approval news underpinned sentiment, while insurers faced more policy and regulatory noise.

The Week Ahead

Macro data picks up next week, led by CPI and core CPI on Wednesday (Oct 14). The market will compare the prior CPI reading of 3.4% with the 3.7% estimate, and core CPI’s 2.4% prior with the 2.5% forecast, both carrying implications for Fed-policy expectations. Tuesday (Oct 13) brings the NFIB Small Business Optimism Index, prior 98.7, and existing-home sales, prior 3.98 with a 3.96 estimate. On the corporate side, UnitedHealth is testing key support ahead of earnings, and TD Cowen has trimmed its price target to $402, making the third-quarter report a key healthcare read for the week.

In Short

XLV.US outpaced the S&P 500 with a 2.79% gain and finished near the top of its 60-day range around $176.595, but valuation looks neutral-to-full rather than cheap, with P/E near 17.15x and P/B near 1.33x. A wave of drug approvals and breakthrough designations supported sentiment, while the latest daily capital snapshot showed large-lot money leaning to the sell side, creating tension between warm research and analyst tone and more cautious money flow. Next week’s CPI and UnitedHealth earnings will test whether the sector can hold its footing at current levels; the path depends on the inflation prints and the managed-care bellwether’s guidance.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.